HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement
of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Latest News
Jun
30
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE ADJUVANT TREATMENT ...
Jun
26
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Jun
26
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER ...
/?php echo file_get_contents("https://www.irasia.com/cgi-local/adaptation/listco/hk/cspc/data.cgi?id=cspc&p=data&t=aclp&layout=home&n=3"); ?>
Financial Reports
2025 Annual Report
Highlight - Results for the first quarter of 2026
Revenue
RMB6,465M, -7.8%
Reported profit attributable to shareholders of the Company
RMB860M, -41.8%
Underlying profit attributable to shareholders of the Company
RMB842M, -40.3%
Basic earnings per share (based on reported profit)
RMB7.54 cents, -41.6%
Key Products
Finished drugs
Bulk drugs
NBP (soft capsules)
NBP (injections)
Oulaining (capsules)
Oulaining (lyophilised powder for injections)
Enxi
Duomeisu
Jinyouli
Keaili
Shuluoke
Nuomoling
Weihong
Xinweihong
Xuanning
Encun
Qixiao
Linmeixin
Shuanglexin
Gubang
Gubangjia
Gaoshunsong
Debixin
Qimaite
Antibiotics
Vitamin C
Caffeine